Literature DB >> 10932288

Retrospective analysis of the use of cyclosporine in myasthenia gravis.

E Ciafaloni1, N K Nikhar, J M Massey, D B Sanders.   

Abstract

The authors reviewed the records of patients with myasthenia gravis who took cyclosporine for at least 6 months between November 1987 and January 1999. Of 57 patients who took cyclosporine for an average of 3.5 years, 55 (96%) had clinical improvement. The median time to best clinical response was 7 months. Corticosteroids were discontinued or decreased in 95% of 38 patients taking them. Major side effects included elevated serum creatinine (28%) and malignancy (11%). Five percent could not afford or tolerate the drug.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10932288     DOI: 10.1212/wnl.55.3.448

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  15 in total

Review 1.  Treatment of myasthenia gravis.

Authors:  Vikas Kumar; Henry J Kaminski
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

Review 2.  Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014.

Authors:  Yoshihisa Kadota; Hirotoshi Horio; Takeshi Mori; Noriyoshi Sawabata; Taichiro Goto; Shin-ichi Yamashita; Takeshi Nagayasu; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-01-22

3.  Myasthenia gravis.

Authors:  Agnes Jani-Acsadi; Robert P Lisak
Journal:  Curr Treat Options Neurol       Date:  2010-05       Impact factor: 3.598

Review 4.  Advances in myasthenia gravis.

Authors:  Emma Ciafaloni; Donald B Sanders
Journal:  Curr Neurol Neurosci Rep       Date:  2002-01       Impact factor: 5.081

5.  Immunosuppression in Multiple Sclerosis and Other Neurologic Disorders.

Authors:  Kaitlyn Koenig Thompson; Stella E Tsirka
Journal:  Handb Exp Pharmacol       Date:  2022

Review 6.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

Review 7.  Advances in autoimmune myasthenia gravis management.

Authors:  Shuhui Wang; Iva Breskovska; Shreya Gandhy; Anna Rostedt Punga; Jeffery T Guptill; Henry J Kaminski
Journal:  Expert Rev Neurother       Date:  2018-07-04       Impact factor: 4.618

8.  Autoimmune Myasthenia Gravis: Recommendations for Treatment and Immunologic Modulation.

Authors:  Vern C Juel; Janice M Massey
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.972

9.  Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.

Authors:  Enrico C Lallana; Camilo E Fadul
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

10.  Treatment of MuSK-Associated Myasthenia Gravis.

Authors:  Khalid El-Salem; Ahmed Yassin; Kefah Al-Hayk; Salma Yahya; Duha Al-Shorafat; Said S Dahbour
Journal:  Curr Treat Options Neurol       Date:  2014-04       Impact factor: 3.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.